Alnylam Pharmaceuticals, Inc. (ALNY)
165.03
+8.38
(+5.35%)
USD |
NASDAQ |
Nov 13, 16:00
165.00
-0.03
(-0.02%)
After-Hours: 19:59
Alnylam Pharmaceuticals Enterprise Value : 20.38B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 20.38B |
| November 11, 2026 | 20.81B |
| November 10, 2026 | 19.71B |
| November 09, 2026 | 20.38B |
| November 06, 2026 | 20.29B |
| November 05, 2026 | 20.38B |
| November 04, 2026 | 20.97B |
| November 03, 2026 | 20.81B |
| November 02, 2026 | 20.56B |
| October 30, 2026 | 21.50B |
| October 29, 2026 | 22.70B |
| October 28, 2026 | 30.52B |
| October 27, 2026 | 29.77B |
| October 26, 2026 | 29.89B |
| October 23, 2026 | 29.40B |
| October 22, 2026 | 29.84B |
| October 21, 2026 | 29.54B |
| October 20, 2026 | 30.30B |
| October 19, 2026 | 30.64B |
| October 16, 2026 | 30.45B |
| October 15, 2026 | 30.74B |
| October 14, 2026 | 29.46B |
| October 13, 2026 | 29.37B |
| October 12, 2026 | 29.80B |
| October 09, 2026 | 30.56B |
| Date | Value |
|---|---|
| October 08, 2026 | 29.47B |
| October 07, 2026 | 29.45B |
| October 06, 2026 | 29.39B |
| October 05, 2026 | 28.85B |
| October 02, 2026 | 28.82B |
| October 01, 2026 | 30.36B |
| September 30, 2026 | 32.44B |
| September 29, 2026 | 33.66B |
| September 28, 2026 | 33.83B |
| September 25, 2026 | 33.91B |
| September 24, 2026 | 33.06B |
| September 23, 2026 | 32.65B |
| September 22, 2026 | 33.33B |
| September 21, 2026 | 32.35B |
| September 18, 2026 | 31.72B |
| September 17, 2026 | 32.51B |
| September 16, 2026 | 31.69B |
| September 15, 2026 | 31.54B |
| September 14, 2026 | 33.11B |
| September 11, 2026 | 32.94B |
| September 10, 2026 | 32.78B |
| September 09, 2026 | 34.18B |
| September 08, 2026 | 34.46B |
| September 04, 2026 | 35.27B |
| September 03, 2026 | 35.05B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 4.834B |
| Vertex Pharmaceuticals, Inc. | 137.73B |
| Pfizer Inc. | 213.03B |
| BridgeBio Pharma, Inc. | 18.15B |
| Cerenome, Inc. | -2.911M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.167B |
| Revenue (Quarterly) | 1.458B |
| Total Expenses (Quarterly) | -709.25M |
| EPS Diluted (Quarterly) | 15.72 |
| Gross Profit Margin (Quarterly) | 75.19% |
| Earnings Yield | 12.00% |
| Operating Earnings Yield | 4.30% |
| Normalized Earnings Yield | 11.58 |